FierceBiotechOriginal article
{"a":[{"_":"Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options","$":{"href":"/biotech/incyte-ditches-development-jak-inhibitor-pursue-next-generation-pipeline","hreflang":"en"}}]}
Phase 1negativeNegative
AI Analysis
Summary
Incyte has discontinued development of a phase 1-stage JAK2 inhibitor for rare blood cancer, choosing to focus on next-generation candidates instead.
Clinical Trial Data
Phase
Phase 1
Outcome Details
Phase 1 JAK2 inhibitor discontinued in favor of next-generation options
Importance:3/10
Sentiment:
-0.30
JAK inhibitorprogram discontinuationrare blood cancerpipeline optimization
Related Companies
Read the original article
Published by FierceBiotech on July 28, 2026 10:33 AM